PL2581113T3 - Przeciwciało anty-tim-3 - Google Patents

Przeciwciało anty-tim-3

Info

Publication number
PL2581113T3
PL2581113T3 PL11792564T PL11792564T PL2581113T3 PL 2581113 T3 PL2581113 T3 PL 2581113T3 PL 11792564 T PL11792564 T PL 11792564T PL 11792564 T PL11792564 T PL 11792564T PL 2581113 T3 PL2581113 T3 PL 2581113T3
Authority
PL
Poland
Prior art keywords
tim
antibody
Prior art date
Application number
PL11792564T
Other languages
English (en)
Inventor
Shin-Ichiro Takayanagi
Hitomi Tomura
Tomonori Tawara
Yoshimasa Inagaki
Tsuguo Kubota
Koichi Akashi
Yoshikane Kikushige
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Kyushu University, National University Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd., Kyushu University, National University Corporation filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of PL2581113T3 publication Critical patent/PL2581113T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
PL11792564T 2010-06-11 2011-06-10 Przeciwciało anty-tim-3 PL2581113T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35383610P 2010-06-11 2010-06-11
PCT/JP2011/063396 WO2011155607A1 (ja) 2010-06-11 2011-06-10 抗ｔｉｍ－３抗体
EP11792564.4A EP2581113B1 (en) 2010-06-11 2011-06-10 Anti-tim-3 antibody

Publications (1)

Publication Number Publication Date
PL2581113T3 true PL2581113T3 (pl) 2018-11-30

Family

ID=45098210

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11792564T PL2581113T3 (pl) 2010-06-11 2011-06-10 Przeciwciało anty-tim-3

Country Status (14)

Country Link
US (3) US8552156B2 (pl)
EP (2) EP2581113B1 (pl)
JP (2) JP6158511B2 (pl)
KR (1) KR101846590B1 (pl)
CN (1) CN103079644B (pl)
AU (1) AU2011262758B8 (pl)
CA (1) CA2814155C (pl)
ES (1) ES2682078T3 (pl)
HU (1) HUE040213T2 (pl)
PL (1) PL2581113T3 (pl)
PT (1) PT2581113T (pl)
TR (1) TR201807750T4 (pl)
TW (1) TWI629483B (pl)
WO (1) WO2011155607A1 (pl)

Families Citing this family (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
CN102046660A (zh) * 2008-03-26 2011-05-04 塞勒兰特治疗公司 骨髓性血液学增殖性病症相关的免疫球蛋白和/或toll样受体蛋白及其用途
ES2571235T3 (es) * 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
MX2012001708A (es) * 2009-08-07 2012-05-22 Kyowa Hakko Kirin Co Ltd Anticuerpo humanizado anti-oligomero de amiloide b.
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
PL2686347T3 (pl) 2011-03-16 2018-10-31 Argenx Bvba Przeciwciała przeciwko CD70
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
SG11201404321YA (en) * 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
CA2916638C (en) * 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
RU2015142815A (ru) 2013-03-14 2017-04-12 Паркаш ГИЛЛ Лечение рака с использованием антител, связывающихся с поверхностным grp78
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
CN104072615B (zh) * 2014-01-26 2016-08-24 中国人民解放军军事医学科学院基础医学研究所 一种能阻断Tim-3信号通路的人Tim-3融合蛋白
AU2015210750B2 (en) * 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
GB201419094D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
AU2015340056A1 (en) * 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
ES2763548T3 (es) * 2014-11-06 2020-05-29 Hoffmann La Roche Anticuerpos anti-TIM3 y procedimientos de uso
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
CN107922484A (zh) * 2015-03-06 2018-04-17 索伦托治疗有限公司 结合tim3的抗体治疗剂
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
EP3277321B1 (en) * 2015-04-01 2024-08-14 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
PL3298021T3 (pl) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Proleki alvocidibu o zwiększonej biodostępności
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
TW201713332A (zh) * 2015-07-14 2017-04-16 協和醱酵麒麟有限公司 包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US11014983B2 (en) 2015-08-20 2021-05-25 Sutro Biopharma, Inc. Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
JP6653054B2 (ja) * 2015-09-17 2020-02-26 ナショナル キャンサー センター Ｔｉｍ−３をターゲットとする脳損傷疾患治療用組成物及びこのスクリーニング方法
ES2839212T3 (es) 2015-09-29 2021-07-05 Inst Nat Sante Rech Med Métodos para determinar el estado metabólico de linfomas B
DK3356411T3 (da) 2015-10-02 2021-09-06 Hoffmann La Roche Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
HK1257518A1 (zh) 2016-01-11 2019-10-25 Novartis Ag 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
EP4035681A1 (en) 2016-01-28 2022-08-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of cancer
WO2017129769A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
RS62736B1 (sr) * 2016-04-12 2022-01-31 Symphogen As Anti-tim-3 antitela i kompozicije
SG11201808909WA (en) 2016-04-13 2018-11-29 Vivia Biotech Sl Ex vivo bite-activated t cells
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3463452A1 (en) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
MX389710B (es) * 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2017214943A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 促进 tim-3 基因表达的慢病毒表达载体及其应用
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
SG11201900026TA (en) * 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
IL264970B2 (en) * 2016-08-26 2024-12-01 Beigene Ltd ANTI–TIM–3 antibodies and their use
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018046738A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
CN109906232B (zh) 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
US20200024352A1 (en) * 2016-12-08 2020-01-23 Eli Lilly And Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
JP2020501589A (ja) 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド がんの治療
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
JP7118073B2 (ja) 2017-01-09 2022-08-15 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法
WO2018146148A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting the response to checkpoint blockade cancer immunotherapy
WO2018146128A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
US11345753B2 (en) 2017-02-27 2022-05-31 Jiangsu Hengrui Medicine Co., Ltd. TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof
EP3600427A1 (en) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
EP4201953A1 (en) 2017-04-03 2023-06-28 F. Hoffmann-La Roche AG Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
KR102737715B1 (ko) 2017-04-05 2024-12-03 르 라보레또레 쎄르비에르 Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JP2020522498A (ja) 2017-06-01 2020-07-30 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１２３ ｃｄ３に結合する二重特異性抗体
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3641739A1 (en) 2017-06-20 2020-04-29 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
EP3658185A4 (en) * 2017-07-28 2021-07-14 Phanes Therapeutics, Inc. ANTI-TIM-3 ANTIBODIES AND USES THEREOF
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
SG11202001211TA (en) 2017-08-28 2020-03-30 Bristol Myers Squibb Co Tim-3 antagonists for the treatment and diagnosis of cancers
JP2020532537A (ja) 2017-08-31 2020-11-12 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US20210060158A1 (en) 2017-09-19 2021-03-04 Institut Curie Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN108794630A (zh) * 2017-12-18 2018-11-13 镇江爱必梦生物科技有限公司 鼠抗人tim3蛋白单克隆抗体制备及其免疫组化用途
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
JP7358361B2 (ja) * 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
EP3740506A1 (en) 2018-01-16 2020-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3756012A1 (en) 2018-02-21 2020-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
CN111867679A (zh) 2018-03-06 2020-10-30 居里研究所 用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂
CN112218658A (zh) 2018-03-12 2021-01-12 国家健康科学研究所 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN110272489B (zh) * 2018-03-15 2023-08-22 上海健信生物医药科技有限公司 一种针对tim-3的全人源化抗体分子, 抗原结合片段及其医药用途
CN110305216B (zh) * 2018-03-20 2022-09-02 无锡智康弘义生物科技有限公司 新型抗tim-3抗体
EP3768725A4 (en) * 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited NEW ANTI-TIM-3 ANTIBODIES
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
WO2019196911A1 (en) * 2018-04-12 2019-10-17 Nanjing Leads Biolabs Co., Ltd. Antibody binding tim-3 and use thereor
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JP7516254B2 (ja) 2018-04-18 2024-07-16 ゼンコア インコーポレイテッド Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
CN111886023B (zh) * 2018-04-24 2024-09-27 安源医药科技（上海）有限公司 针对tim-3的抗体及其用途
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
WO2019232528A1 (en) 2018-06-01 2019-12-05 Xencor, Inc. Dosing of a bispecific antibody that bind cd123 and cd3
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3810189A1 (en) 2018-06-19 2021-04-28 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
TW202016145A (zh) * 2018-06-29 2020-05-01 財團法人生物技術開發中心 抗人類tim-3之人類化抗體及其用途
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CU20210002A7 (es) 2018-07-10 2021-08-06 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
CN112566936B (zh) * 2018-08-21 2024-07-12 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体
US20210261663A1 (en) * 2018-08-28 2021-08-26 Jiangsu Hengrui Medicine Co., Ltd. Anti-tim3 antibody pharmaceutical composition and use thereof
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
WO2020070053A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
US20210340240A1 (en) 2018-10-18 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
CN110655566B (zh) * 2018-10-25 2021-06-18 浙江大学 可溶性Tim-3重组蛋白及其突变型蛋白的制备和应用
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US20230183379A1 (en) 2018-11-20 2023-06-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
ES2971964T3 (es) 2018-11-28 2024-06-10 Inst Nat Sante Rech Med Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN113195538B (zh) * 2018-12-12 2023-03-14 上海药明生物技术有限公司 抗tim-3抗体及其用途
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
EP3897624A1 (en) 2018-12-17 2021-10-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of sulconazole as a furin inhibitor
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
JP2022514280A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー Ｍｄｍ２阻害剤のための延長低用量レジメン
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
WO2020128636A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
KR20210121077A (ko) 2019-01-15 2021-10-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
EP3918332B1 (en) 2019-01-30 2025-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
US20220117911A1 (en) 2019-02-04 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020206169A1 (en) 2019-04-02 2020-10-08 Kupper Thomas S Methods for identifying progression of a primary melanoma
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220160692A1 (en) 2019-04-09 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
CN110498855A (zh) * 2019-07-25 2019-11-26 钟小泉 一种tim-3抗体及其用途
CN110407938B (zh) * 2019-08-12 2020-03-06 北京昭衍生物技术有限公司 抗tim-3单克隆抗体、表达载体及其应用
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2022548627A (ja) * 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CN113166264B (zh) * 2019-09-19 2024-02-27 上药生物治疗（香港）有限公司 一种分离的抗原结合蛋白及其用途
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2021064180A1 (en) 2019-10-03 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
EP4037710A1 (en) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
AU2020361683A1 (en) 2019-10-11 2022-05-19 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
US20240301497A1 (en) 2019-10-17 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
CA3158298A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
US20240122938A1 (en) 2019-10-29 2024-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
CN114599372A (zh) 2019-11-04 2022-06-07 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
JP7807076B2 (ja) 2019-12-13 2026-01-27 キュージーン インコーポレイテッド 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3164754A1 (en) 2019-12-19 2021-06-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and vaccine compositions to treat cancers
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
EP4090770A1 (en) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021156360A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
TW202146452A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021175191A1 (zh) * 2020-03-02 2021-09-10 信达生物制药(苏州)有限公司 抗tim-3抗体及其用途
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4157460A1 (en) 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
WO2022002874A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
JP7856627B2 (ja) 2020-07-28 2026-05-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンを予防及び処置するための方法及び組成物
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
CA3190660A1 (en) 2020-08-31 2022-03-03 George C. Lee Cell localization signature and immunotherapy
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US12577621B2 (en) 2020-09-08 2026-03-17 Duke University LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
EP4244392A1 (en) 2020-11-16 2023-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for predicting and treating uveal melanoma
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
CA3204162A1 (en) 2021-01-11 2022-07-14 Robert Kastelein Compositions and methods related to receptor pairing
CN112961239B (zh) * 2021-02-24 2021-09-10 北京昭衍生物技术有限公司 Tim抑制剂及其应用
CN112979809B (zh) * 2021-02-24 2021-11-09 北京昭衍生物技术有限公司 一种与抗原tim-3结合的靶向分子
WO2022194908A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
JP2024516616A (ja) 2021-04-23 2024-04-16 スゾウ ネオロジクス バイオサイエンス シーオー．， エルティーディー． Ｔｉｍ－３を標的とする抗体及びその使用
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
EP4370139A4 (en) 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
US20240426823A1 (en) 2021-11-03 2024-12-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating triple negative breast cancer (tnbc)
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用
AU2022409713A1 (en) 2021-12-16 2024-06-20 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
CN119384289A (zh) 2022-04-13 2025-01-28 免疫生物公司 用于治疗神经炎症性障碍的多链嵌合多肽
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN119562830A (zh) 2022-06-02 2025-03-04 百时美施贵宝公司 抗体组合物及其使用方法
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024052356A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
EP4604939A1 (en) 2022-10-20 2025-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination therapy for the treatment of cancer
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
EP4608390A1 (en) 2022-10-24 2025-09-03 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024150017A1 (en) 2023-01-13 2024-07-18 Akrivia Biomedics Limited Method of profiling diseases
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024161015A1 (en) 2023-02-03 2024-08-08 Institut National de la Santé et de la Recherche Médicale Method to treat age-related diseases
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
EP4687990A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025003193A1 (en) 2023-06-26 2025-01-02 Institut National de la Santé et de la Recherche Médicale Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025068180A1 (en) 2023-09-25 2025-04-03 Institut National de la Santé et de la Recherche Médicale Methods of treatment of cancer by targetting cancer - associated fibroblasts
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025210175A1 (en) 2024-04-04 2025-10-09 Centre National De La Recherche Scientifique Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025219595A1 (en) 2024-04-19 2025-10-23 Biper Therapeutics Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses
WO2026012976A1 (en) 2024-07-08 2026-01-15 Institut National de la Santé et de la Recherche Médicale Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026013071A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Setdb1 inhibitor for use in the treatment of uveal melanoma
WO2026037841A1 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
WO2026043909A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2026043906A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026052851A2 (en) 2024-09-09 2026-03-12 Institut National de la Santé et de la Recherche Médicale Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
WO2026093526A1 (en) 2024-10-31 2026-05-07 Institut National de la Santé et de la Recherche Médicale Methods of predicting cancer in patients having premalignant lesions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
JP2564268B2 (ja) 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α２→３シアリルトランスフェラーゼ
EP0643132B1 (en) 1993-03-29 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Alpha-1,3-fucosyltransferase
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
DK2314686T4 (da) * 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
WO2005097211A2 (en) 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions as adjuvants to improve immune responses to vaccines and methods of use
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CA2668693A1 (en) * 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
US9274119B2 (en) * 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
CA3108119C (en) 2008-01-15 2024-01-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体

Also Published As

Publication number Publication date
US20120189617A1 (en) 2012-07-26
TWI629483B (zh) 2018-07-11
ES2682078T3 (es) 2018-09-18
KR101846590B1 (ko) 2018-04-09
TR201807750T4 (tr) 2018-06-21
CN103079644A (zh) 2013-05-01
JP2017189168A (ja) 2017-10-19
US20140044728A1 (en) 2014-02-13
JP6158511B2 (ja) 2017-07-05
EP2581113A1 (en) 2013-04-17
EP3363499A1 (en) 2018-08-22
US10550181B2 (en) 2020-02-04
CA2814155A1 (en) 2011-12-15
KR20130132695A (ko) 2013-12-05
CN103079644B (zh) 2017-02-15
EP2581113B1 (en) 2018-05-09
AU2011262758A8 (en) 2014-09-04
US9556270B2 (en) 2017-01-31
WO2011155607A1 (ja) 2011-12-15
US20170088616A1 (en) 2017-03-30
AU2011262758B2 (en) 2014-04-24
AU2011262758B8 (en) 2014-09-04
CA2814155C (en) 2019-10-22
US8552156B2 (en) 2013-10-08
AU2011262758A1 (en) 2013-01-10
EP2581113A4 (en) 2013-12-25
PT2581113T (pt) 2018-07-04
HUE040213T2 (hu) 2019-02-28
TW201207397A (en) 2012-02-16
JPWO2011155607A1 (ja) 2013-08-15

Similar Documents

Publication Publication Date Title
HUS1900020I1 (hu) CGRP ellenanyagok
IL259826A (en) Anti-alphabetatisiar antibody
HUE040213T2 (hu) Anti-TIM antitest
PL2530091T3 (pl) Przeciwciało przeciwko dll3
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
ZA201302459B (en) Antibodies
ZA201307983B (en) Anti-b7-h3 antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
IL225667A0 (en) A new antigen
GB201020738D0 (en) Antibodies
PT2603528T (pt) Anticorpos glicosilados em fab
GB201002238D0 (en) Antibodies
TWI563004B (en) Anti-hxcr1 antibody
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201007957D0 (en) Antibody
GB201017780D0 (en) Antibody
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies
GB201017523D0 (en) Diceshaker